Publications by authors named "J Braunstein"
Article Synopsis
- Diagnosing Alzheimer's disease is tough for doctors, which can lead to delays in getting the right care for patients.
- Blood tests that check for signs of Alzheimer's could help doctors find the disease earlier and treat it better, but there are still some big challenges to overcome.
- A special group of leaders in Alzheimer's research is working on solutions, like creating better guidelines, training healthcare workers, and making sure patients understand their test results.
Article Synopsis
- Blood-based biomarkers (BBMs) are new tests that help doctors check for Alzheimer's disease in a simpler and cheaper way than older methods like brain scans or spinal fluid tests.! -
- A special group called the Global CEO Initiative on Alzheimer's Disease is suggesting two ways to use these BBMs: one for initial testing and another to confirm more serious cases.! -
- Using BBMs can make it easier for doctors to diagnose Alzheimer's, which means that patients can start getting needed treatments faster.!
PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology.
Stephanie M Eastwood Matthew R Meyer Kristopher M Kirmess Traci L Wente-Roth Faith Irvin Joel B Braunstein
Diagnostics (Basel)
August 2024
Alzheimer's disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities. Recently, less burdensome, more widely available blood biomarker (BBM) assays for amyloid-beta (Aβ42/40) and phosphorylated-tau concentrations have been found to accurately identify the presence/absence of brain amyloid plaques and tau tangles and have helped to streamline AD diagnosis.
View Article and Find Full Text PDFArticle Synopsis
- Phase 3 trials have shown that antiamyloid therapies are more effective in patients with milder Alzheimer disease, highlighting the need for plasma biomarkers in screening cognitively unimpaired individuals at risk of amyloid accumulation.
- This longitudinal study aimed to determine if a combination of specific plasma biomarkers could predict the onset of Aβ pathology in cognitively unimpaired individuals with low baseline brain Aβ levels.
- Results from multiple cohorts revealed that combining plasma %p-tau217 and Aβ42/40 levels significantly improved the detection of abnormal Aβ status, indicating a promising strategy for early intervention in Alzheimer's disease.
Article Synopsis
- Researchers aimed to evaluate a blood test for Alzheimer’s disease (AD) to simplify diagnosis and treatment in both primary and secondary care settings.* -
- The study involved 1213 patients with cognitive symptoms, measuring specific biomarkers in their plasma to determine the presence of AD pathology.* -
- Results showed that about 50% of the patients had AD pathology, with data collected indicating significant diagnostic accuracy and potential for practical application.*